ASCO Conference Coverage
Researchers report 3 percent annual rise in intermediate- and high-risk cases
When active surveillance is chosen, survival for intermediate-risk disease may be decreased.
Individuals who've had testicular cancer may be at increased risk for prostate cancer, but the overall risk is low, according to a study.
Guideline outlines recommended follow-up care for prostate cancer survivors
Certain types of cancer patients tended to have lower vitamin D levels
The endorsed guideline outlines use of adjuvant and salvage radiotherapy after surgery for prostate cancer.
A majority of of palliative care clinicians report burnout, according to a study, with the greatest risk of burnout for younger clinicians and those working more than 50 hours per week
Most patients use lifestyle-altering strategies and about 40 percent adopt a care-altering strategy to manage financial distress associated with their cancer care.
Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.
A new immunotherapy vaccine candidate for breast cancer shows promise, having reduced recurrence rate by more than fifty percent.
- Study may support active surveillance for favorable intermediate-risk prostate cancer
- New mechanism of acquired resistance to breast cancer drugs discovered
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- Finding a qualified acupuncture practitioner
- New opportunity to treat drug-resistant leukemia discovered
- High-cost blood cancer drugs deliver high value
- Statins increase risk of diabetes in Caucasian men
- Sun damage predisposes pediatric patients to melanoma
- Risk of reproductive cancers increased in daughters of women who smoked during pregnancy
- Older white males with advanced bladder cancer more likely to commit suicide
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|